Novel biomarkers of metastatic cancer

被引：11

作者：

Dawood, Shaheenah ^{[1
]}

机构：

[1] Dubai Hosp, Dubai Hlth Author, Dept Med Oncol, Dubai, U Arab Emirates

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2010年 / 10卷 / 05期

关键词：

biomarkers; BRAF; circulating tumor cells; HER2; KRAS; metastatic cancer; microRNA; CIRCULATING TUMOR-CELLS; GROWTH-FACTOR RECEPTOR; PREDICT PROGRESSION-FREE; GENE COPY NUMBER; BREAST-CANCER; LUNG-CANCER; COLORECTAL-CANCER; PHASE-III; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1586/ERM.10.35

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Once metastatic disease is documented, cure is no longer the goal and the disease is generally associated with poor outcomes, with the majority of patients dying of their disease rather than other causes. The last three decades have seen significant advances in the genomics, proteomics and molecular pathology of biomarkers in cancer, allowing for individualization of therapy that has significantly and positively impacted survival outcomes. Genetic signatures have been identified that can predict not only the future development of metastases, but also the development of specific sites of metastases. Protein biomarkers have been identified that are in use clinically for the monitoring of both disease progression and therapeutic efficacy. DNA- and RNA-based biomarkers have also been identified. This review will focus on some of the novel biomarkers that have been developed over the last decade.

引用

页码：581 / 590

页数：10

共 98 条

[71] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J].

Piccart-Gebhart, MJ ;

Procter, M ;

Leyland-Jones, B ;

Goldhirsch, A ;

Untch, M ;

Smith, I ;

Gianni, L ;

Baselga, J ;

Bell, R ;

Jackisch, C ;

Cameron, D ;

Dowsett, M ;

Barrios, CH ;

Steger, G ;

Huang, CS ;

Andersson, M ;

Inbar, M ;

Lichinitser, M ;

Láng, I ;

Nitz, U ;

Iwata, H ;

Thomssen, C ;

Lohrisch, C ;

Suter, TM ;

Ruschoff, J ;

Süto, T ;

Greatorex, V ;

Ward, C ;

Straehle, C ;

McFadden, E ;

Dolci, MS ;

Gelber, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1659-1672

[72] Cancer of unknown primary origin: a decade of experience in a community-based hospital [J].

Pimiento, Jose M. ;

Teso, Desarom ;

Malkan, Alpin ;

Dudrick, Stanley J. ;

Palesty, J. Alexander .

AMERICAN JOURNAL OF SURGERY, 2007, 194 (06) :833-838

[73] Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial [J].

Pirker, Robert ;

Pereira, Jose R. ;

Szczesna, Aleksandra ;

von Pawel, Joachim ;

Krzakowski, Maciej ;

Ramlau, Rodryg ;

Vynnychenko, Ihor ;

Park, Keunchil ;

Yu, Chih-Teng ;

Ganul, Valentyn ;

Roh, Jae-Kyung ;

Bajetta, Emilio ;

O'Byrne, Kenneth ;

de Marinis, Filippo ;

Eberhardt, Wilfried ;

Goddemeier, Thomas ;

Emig, Michael ;

Gatzemeier, Ulrich ;

Pirker, R. ;

Thatcher, N. ;

Armand, J. P. ;

Camus, P. ;

Victor, N. ;

Emig, M. ;

Mueser, M. ;

Pilz, K. ;

Goddemeier, T. ;

Montaner, I. ;

Lachs, Martin ;

Hoang-Sayag, Loan ;

Alvarez, A. ;

Coppola, F. ;

Recondo, G. ;

Richardet, E. ;

Kirsten, F. ;

Karapetis, C. ;

Parente, P. ;

Michael, M. ;

White, S. ;

Boyce, A. ;

Lewis, C. ;

Slancar, M. ;

Pavlakis, N. ;

Abdi, E. ;

Underhill, C. ;

Pittman, K. ;

Burghuber, O. ;

Pirker, R. ;

Ruckser, R. ;

Ulsperger, E. .

LANCET, 2009, 373 (9674) :1525-1531

[74] PATHOGENESIS OF CANCER METASTASIS [J].

POSTE, G ;

FIDLER, IJ .

NATURE, 1980, 283 (5743) :139-146

[75] A molecular signature of metastasis in primary solid tumors [J].

Ramaswamy, S ;

Ross, KN ;

Lander, ES ;

Golub, TR .

NATURE GENETICS, 2003, 33 (01) :49-54

[76] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J].

Romond, EH ;

Perez, EA ;

Bryant, J ;

Suman, VJ ;

Geyer, CE ;

Davidson, NE ;

Tan-Chiu, E ;

Martino, S ;

Paik, S ;

Kaufman, PA ;

Swain, SM ;

Pisansky, TM ;

Fehrenbacher, L ;

Kutteh, LA ;

Vogel, VG ;

Visscher, DW ;

Yothers, G ;

Jenkins, RB ;

Brown, AM ;

Dakhil, SR ;

Mamounas, EP ;

Lingle, WL ;

Klein, PM ;

Ingle, JN ;

Wolmark, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1673-1684

[77] MicroRNAs accurately identify cancer tissue origin [J].

Rosenfeld, Nitzan ;

Aharonov, Ranit ;

Meiri, Eti ;

Rosenwald, Shai ;

Spector, Yael ;

Zepeniuk, Merav ;

Benjamin, Hila ;

Shabes, Norberto ;

Tabak, Sarit ;

Levy, Asaf ;

Lebanony, Danit ;

Goren, Yaron ;

Silberschein, Erez ;

Targan, Nurit ;

Ben-Ari, Alex ;

Gilad, Shlomit ;

Sion-Vardy, Netta ;

Tobar, Ana ;

Feinmesser, Meora ;

Kharenko, Oleg ;

Nativ, Ofer ;

Nass, Dvora ;

Perelman, Marina ;

Yosepovich, Ady ;

Shalmon, Bruria ;

Polak-Charcon, Sylvie ;

Fridman, Eddie ;

Avniel, Amir ;

Bentwich, Isaac ;

Bentwich, Zvi ;

Cohen, Dalia ;

Chajut, Ayelet ;

Barshack, Iris .

NATURE BIOTECHNOLOGY, 2008, 26 (04) :462-469

[78]

Rusch V, 1997, CLIN CANCER RES, V3, P515

[79] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [J].

Saltz, LB ;

Meropol, NJ ;

Loehrer, PJ ;

Needle, MN ;

Kopit, J ;

Mayer, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1201-1208

[80] PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies [J].

Sartore-Bianchi, Andrea ;

Martini, Miriam ;

Molinari, Francesca ;

Veronese, Silvio ;

Nichelatti, Michele ;

Artale, Salvatore ;

Di Nicolantonio, Federica ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Mazzucchelli, Luca ;

Frattini, Milo ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2009, 69 (05) :1851-1857

← 1 2 3 4 5 6 7 8 9 10 →